



European
Innovation
Council



bpifrance

NETRIS Pharma Receives Best Biotech Pitch Award at EIC and Johnson & Johnson Healthcare Investor Day (powered by Bpifrance – Euroquity)

NETRIS Pharma Recognized as a Leading EIC Accelerator Alumni

November 13th, 2024 - LYON, France and GENEVA, Switzerland– Netris Pharma proudly announces the successful award of the Best Biotech Pitch during the Pharma Session at the EIC and Johnson & Johnson Investor Day, powered by Bpifrance – Euroquity. The event, held in Paris on November 13th, 2024, brought together some of the most impactful life science companies supported by the EIC Accelerator as well as a selection of high profile LifeScience investors.

“This award is a strong recognition of NETRIS Pharma's innovative approach to overcoming resistance to existing treatments in oncology,” said Christophe Guichard, Chief Financial Officer of NETRIS Pharma. *“It highlights our progress throughout 2024 and momentum, from our successful application to the EIC Accelerator in 2021 and our selection as one of the first 15 life science companies to participate in the EIC Soft Landing Program in San Francisco in May 2024. Building on our promising preliminary clinical outcomes in locally advanced pancreatic cancer patients, we eagerly anticipate 2025, which will bring a wealth of clinical outcomes from our five ongoing clinical studies”,* he added.

Patrick Mehlen, Chief Executive Officer and Founder of NETRIS Pharma, commented, *“The EIC Fund and Bpifrance have been invaluable partners in our journey, and we are excited to further strengthen our collaboration as we continue to advance NP137, our potential first-in-class anti-Netrin-1 antibody to improve treatment outcome for oncology patients”.*

About NETRIS Pharma

NETRIS Pharma is a clinical-stage biopharmaceutical company developing innovative therapeutic molecules targeting NETRIN-1, a protein aberrantly expressed in cancer cells that triggers EMT, one of the main cause of resistance to oncology therapies. NETRIN-1 has also been reported in other proliferation disorders such as endometriosis and fibrosis. Our lead product, NP137, is the most advanced product candidate targeting NETRIN-1 and its mode-of-action has been published in Nature® in 2023.

Further information can be found at: <https://www.netrispharma.com>.

Contacts:

NETRIS Pharma

Christophe GUICHARD, CFO and IR,

christopheguichard@netrispharma.com